RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.44
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$28.62

11 May
2026

0.060

OPEN

$28.60

0.21%

HIGH

$28.65

1,082,654

LOW

$28.23

TARGET
$44.405 55.2% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 167.7 xxx
DPS (cps) 36.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 16.5 xxx
Dividend Yield 1.3% xxx
Div Pay Ratio(%) 22.0% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.83%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.06

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 12/11 - (franking ex-div 6c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx147.4
DPS All xxxxxxxxxxxxxxx32.5
Sales/Revenue xxxxxxxxxxxxxxx7,946.4 M
Book Value Per Share xxxxxxxxxxxxxxx622.1
Net Operating Cash Flow xxxxxxxxxxxxxxx2,704.6 M
Net Profit Margin xxxxxxxxxxxxxxx27.22 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx26.39 %
Return on Invested Capital xxxxxxxxxxxxxxx22.91 %
Return on Assets xxxxxxxxxxxxxxx19.00 %
Return on Equity xxxxxxxxxxxxxxx26.39 %
Return on Total Capital xxxxxxxxxxxxxxx27.43 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2,085.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx62 M
Long Term Debt xxxxxxxxxxxxxxx1,238 M
Total Debt xxxxxxxxxxxxxxx1,300 M
Goodwill - Gross xxxxxxxxxxxxxxx4,649 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx1,865 M
Price To Book Value xxxxxxxxxxxxxxx6.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx155.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.96 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,299 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2,042 M
Research & Development xxxxxxxxxxxxxxx512 M
Investments - Total xxxxxxxxxxxxxxx108 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

04/05/2026

1

Outperform

$46.50

62.47%

ResMed has maintained gross margin guidance for FY26 at 62-63% while, geographically, the rest of the world has outperformed in both devices and masks. In contrast, the Americas was -2% below Macquarie's estimates in both categories.

The AS11 roll-out in China should support ongoing growth in rest of the world and the company has acquired Noctrix for -US$340m which has an FDA De Novo classified device for moderate-severe restless leg syndrome. The broker now captures this acquisition in its forecasts.

Outperform maintained. Target edges down to $46.50 from $47.50.

FORECAST
Macquarie forecasts a full year FY26 dividend of 35.79 cents and EPS of 165.55 cents.
Macquarie forecasts a full year FY27 dividend of 37.58 cents and EPS of 190.16 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

(xx/xx/xxxx)

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

05/05/2026

2

Overweight

$42.70

49.20%

Jarden maintains an Overweight rating for ResMed while lowering its target price to $42.70 from $44.80 following what is labeled a solid third-quarter result.

The medical device manufacturer delivered 19.7% net profit growth, overcoming a slight -1% revenue miss in US devices through strong rest-of-world sales and robust gross margin expansion driven by production efficiencies.

Management anticipates these productivity gains will offset ongoing inflationary pressures across electronic components and plastics heading into FY27.

The broker trimmed its FY26 earnings per share forecast to US111.8c from US112.4c to account for near-term dilution from the US$340m acquisition of Noctrix Health, an FDA-approved neurostimulation therapy provider for restless leg syndrome.

Jarden views the stock as attractively valued given its double-digit earnings growth profile, ongoing share buybacks, and expanding total addressable market.

FORECAST
Jarden forecasts a full year FY26 dividend of 369.87 cents and EPS of 166.74 cents.
Jarden forecasts a full year FY27 dividend of 416.11 cents and EPS of 189.41 cents.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
April In Review: An Inflection Point

May 06 2026 - Australia
2
Rudi’s View: AI, The Great Market Divider

May 06 2026 - Rudi's View
3
Australian Broker Call *Extra* Edition – May 05, 2026

May 05 2026 - Daily Market Reports
4
FNArena Corporate Results Monitor – 04-05-2026

May 04 2026 - Australia
5
Australian Broker Call *Extra* Edition – Apr 30, 2026

Apr 30 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
2
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
3
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
4
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
5
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
6
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
7
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
8
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
9
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
10
ResMed’s New Level Of Support

Jul 29 2025 - Technicals